Compare RELL & RNAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RELL | RNAC |
|---|---|---|
| Founded | 1947 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.7M | 243.0M |
| IPO Year | 2004 | 2016 |
| Metric | RELL | RNAC |
|---|---|---|
| Price | $17.07 | $8.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | ★ 369.7K | 317.4K |
| Earning Date | 04-08-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.75% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $208,909,000.00 | $2,797,000.00 |
| Revenue This Year | $6.32 | N/A |
| Revenue Next Year | $7.91 | N/A |
| P/E Ratio | $230.96 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.79 | $5.60 |
| 52 Week High | $19.86 | $14.56 |
| Indicator | RELL | RNAC |
|---|---|---|
| Relative Strength Index (RSI) | 55.62 | 60.02 |
| Support Level | $10.10 | $6.18 |
| Resistance Level | $19.86 | $9.97 |
| Average True Range (ATR) | 1.11 | 0.95 |
| MACD | -0.18 | 0.09 |
| Stochastic Oscillator | 42.59 | 64.89 |
Richardson Electronics Ltd provides engineered solutions, power grid, and microwave tubes and related consumables, power conversion, RF and microwave components, high-value flat panel detector solutions, replacement parts, tubes, and service training for diagnostic imaging equipment and customized display solutions. The company's segment includes Power and Microwave Technologies, Green Energy Solutions, Canvys, and Healthcare. The company generates the majority of its revenue from the Power and Microwave Technologies segment, which includes the power grid and microwave tube business and RF, Wireless and Power technologies.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.